Enthalpy versus Entropy-Driven Binding of Bisphosphonates to Farnesyl Diphosphate Synthase
- 23 February 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 128 (11) , 3524-3525
- https://doi.org/10.1021/ja0601639
Abstract
We report the results of an ITC (isothermal titration calorimetry) investigation of the binding of six bisphosphonates to the enzyme farnesyl diphosphate synthase (FPPS; EC 2.5.1.10) from Trypanosoma brucei. The bisphosphonates investigated were zoledronate, risedronate, ibandronate, pamidronate, 2-phenyl-1-hydroxyethane-1,1-bisphosphonate, and 1-(2,2-bisphosphonoethyl)-3-iodo pyridinium. At pH = 7.4, both risedronate and the phenylethane bisphosphonate bind in an enthalpy-driven manner (ΔH ∼ −9 to 10 kcal mol-1), but the other four bisphosphonates bind in an entropy-driven manner (ΔS varying from 31.2 to 55.1 cal K-1 mol-1). However, at pH = 8.5, zoledronate binding switches from entropy to enthalpy-driven. The ΔG results are highly correlated with FPPS inhibition results obtained using a radiochemical assay (R2 = 0.85, N = 11, P < 0.001). The ΔH and ΔS results are interpreted in terms of a model in which bisphosphonates with charged side chains have positive ΔH values, due to the enthalpic cost of desolvation (due to strong ion−dipole interactions) and, likewise, a positive ΔS, due to an increase in water entropy (both ligand and protein associated) on ligand binding to FPPS: the hydrophobic effect. For the neutral side chains (risedronate at pH 7.4, 8.5 and zoledronate at pH 8.5, as well as the phenylethane bisphosphonate), binding is overwhelmingly enthalpy-driven, with the enhanced activity of the basic side chain containing species being attributable to their becoming protonated in the active site. Given the large size of the bisphosphonate market and the potential importance of the development of these compounds for cancer immunotherapy and anti-parasitic chemotherapy, these results are of broad general interest in the context of the development of new, potent, and selective FPPS inhibitors.Keywords
This publication has 12 references indexed in Scilit:
- Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: Implications for drug designProteins-Structure Function and Bioinformatics, 2005
- ITC in the post-genomic era…? PricelessPublished by Elsevier ,2004
- Quantitative Structure−Activity Relationships for γδ T Cell Activation by BisphosphonatesJournal of Medicinal Chemistry, 2003
- 3-D QSAR Investigations of the Inhibition ofLeishmaniamajorFarnesyl Pyrophosphate Synthase by BisphosphonatesJournal of Medicinal Chemistry, 2003
- Bisphosphonates in osteoporosisEuropean Spine Journal, 2003
- γδ T cells for immune therapy of patients with lymphoid malignanciesBlood, 2003
- Radical Cure of Experimental Cutaneous Leishmaniasis by the Bisphosphonate PamidronateThe Journal of Infectious Diseases, 2002
- In Vivo Activities of Farnesyl Pyrophosphate Synthase Inhibitors against Leishmania donovani and Toxoplasma gondiiAntimicrobial Agents and Chemotherapy, 2002
- Bisphosphonates Inhibit the Growth ofTrypanosomabrucei,Trypanosomacruzi,Leishmaniadonovani,Toxoplasmagondii, andPlasmodiumfalciparum: A Potential Route to ChemotherapyJournal of Medicinal Chemistry, 2001
- Nitrogen-Containing Bisphosphonates as Carbocation Transition State Analogs for Isoprenoid BiosynthesisBiochemical and Biophysical Research Communications, 1999